Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers ! Shipping Price Reduction for EU Regions
Human IL-2RB&IL-2RA&IL-2RG, His Tag&Twin Strep Tag (Cat. No. ILG-H52W9) captured on CM5 chip via anti-His antibody can bind Human IL-2, Tag Free with an affinity constant of 56.9 pM as determined in a SPR assay (Biacore 8K) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | HIV Wasting Syndrome; Angiodysplasia; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Osteosarcoma; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Erythema Nodosum; Drug Resistant Epilepsy; Xerostomia; Sarcoma; Pancreatitis, Chronic; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Arachnoiditis; Carcinoma, Adenosquamous; Gastrointestinal Hemorrhage; Cholangitis, Sclerosing; Prostatic Neoplasms; Pelvic Pain; Neoplasm Metastasis; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Tuberculosis; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Anemia, Sideroblastic; Glioma; Leprosy, Lepromatous; Endometrial Neoplasms; Lung Neoplasms; Waldenstrom Macroglobulinemia; Kidney Neoplasms; Thalassemia; Carcinoid Tumor; Lupus Erythematosus, Discoid | Details |
| Thalidomide | NSC-66847; NSC-527179; K-17; VP-02; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | HIV Wasting Syndrome; Angiodysplasia; Primary Myelofibrosis; Neuroectodermal Tumors, Primitive; Prostatitis; Colorectal Neoplasms; Osteosarcoma; Lymphoma, Mantle-Cell; Sarcoma, Ewing; Retinoblastoma; Erythema Nodosum; Drug Resistant Epilepsy; Xerostomia; Sarcoma; Pancreatitis, Chronic; Adenocarcinoma, Clear Cell; Lymphoma, Follicular; Arachnoiditis; Carcinoma, Adenosquamous; Gastrointestinal Hemorrhage; Cholangitis, Sclerosing; Prostatic Neoplasms; Pelvic Pain; Neoplasm Metastasis; Stomatitis; Burning Mouth Syndrome; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Tuberculosis; Appendiceal Neoplasms; Lymphoma, Non-Hodgkin; Uterine Neoplasms; Anemia, Sideroblastic; Glioma; Leprosy, Lepromatous; Endometrial Neoplasms; Lung Neoplasms; Waldenstrom Macroglobulinemia; Kidney Neoplasms; Thalassemia; Carcinoid Tumor; Lupus Erythematosus, Discoid | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase 3 Clinical | Philogen Spa | Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Carcinoma, Skin Appendage; Keratoacanthoma; Basal Cell Nevus Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi | Details |
| Bifikafusp alfa | L19-IL-2 | Phase 3 Clinical | Philogen Spa | Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| BNZ-1 | BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01; EQ101; EQ-101 | Phase 2 Clinical | Bioniz Therapeutics Inc | Alopecia; Alopecia Areata; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic | Details |
| umitrelimorgene autodencel | ITI-1000 | Phase 2 Clinical | Immunomic Therapeutics Inc | Glioblastoma | Details |
| S-95007 | S-95007 | Phase 2 Clinical | Laboratoires Servier | Immune System Diseases; Inflammation | Details |
| AU-007 | BD-8; AU-007; BDG-8 | Phase 2 Clinical | Biolojic Design Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| XTX-202 | XTX-202 | Phase 2 Clinical | Xilio Development Inc, Xilio Therapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Melanoma | Details |
| LAT-010 | LAT010; LAT-010 | Phase 2 Clinical | Latticon Antibody Therapeutics Inc | Solid tumours | Details |
| COYA-302 | COYA302; COYA 302; COYA-302 | Phase 2 Clinical | Coya Therapeutics Inc | Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis | Details |
| AVB-001 | AVB-001 | Phase 2 Clinical | Avenge Bio Inc | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| Saltikva | Phase 2 Clinical | Salspera LLC | Pancreatic Neoplasms | Details | |
| LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) | Phase 2 Clinical | Tcrcure Biopharma Ltd | Nasopharyngeal Carcinoma | Details | |
| Interleukin-2 gene therapy (St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital, National Cancer Institute | Neuroblastoma | Details | |
| T20K | T-20K | Phase 1 Clinical | Cyxone | Multiple Sclerosis | Details |
| SIM-0278 | ALM-223; SIM0278 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic; Dermatitis, Atopic | Details |
| Mableukin 2PD1 (Anwita Biosciences) | AWT020; AWT-020 | Phase 1 Clinical | Anwita Biosciences Inc | Neoplasms; Autoimmune Diseases of the Nervous System | Details |
| AB-248 | AB-248 | Phase 1 Clinical | Asher Biotherapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| ASP-1012 | VET2-L2; ASP-1012; ASP1012 | Phase 1 Clinical | KaliVir Immunotherapeutics Inc | Solid tumours | Details |
| STK-012 | STK-012 | Phase 1 Clinical | Synthekine Inc | Solid tumours; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| IL2 CD25 fusion protein (Bristol-Myers Squibb) | Phase 1 Clinical | University Of Miami | Autoimmune Diseases | Details | |
| M5A-IL2 Immunocytokine | M5A-ICK | Phase 1 Clinical | National Cancer Institute, City Of Hope National Medical Center | Breast Neoplasms; Colorectal Neoplasms | Details |
| DF-6215 | DF6215; DF-6215 | Phase 1 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
| Dodekin | Phase 1 Clinical | Philogen Spa | Solid tumours; Neoplasm Metastasis | Details | |
| KB-707 | KB-707; KB707 | Phase 1 Clinical | Krystal Biotech Inc | Solid tumours; Skin Melanoma; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Neoplasms; Sarcoma; Osteosarcoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular | Details |
| attIL2-T cell therapy | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Soft Tissue Neoplasms; Osteosarcoma; Sarcoma | Details | |
| Autologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics) | HV-101; HV101 | Phase 1 Clinical | Hervor Therapeutics, Tcrcure Biopharma Ltd, Hangzhou Houwu Biomedical Technology Co Ltd | Solid tumours | Details |
| KY-0118 | KY-0118; KY0118 | Phase 1 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| VIS171 | VIS-171; VIS171 | Phase 1 Clinical | Visterra Inc | Autoimmune Diseases | Details |
| MK-1484 | MK-1484; SP-482 | Phase 1 Clinical | Merck & Co Inc, Sutro Biopharma Inc | Solid tumours | Details |
| SAR-444336 | SAR-444336 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| RS-2102 | RS2102 | Phase 1 Clinical | Reistone Biopharma Co Ltd | Dermatitis, Atopic | Details |
| RG-6279 | RG-6279 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
| BNT-153 | BNT-153 | Phase 1 Clinical | Biontech Se | Solid tumours | Details |
| Igrelimogene litadenorepvec | PM-1016; PM1016; TILT-123 | Phase 1 Clinical | Tilt Biotherapeutics Ltd | Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Melanoma; Carcinoma, Hepatocellular | Details |
| Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase 3 Clinical | Philogen Spa | Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Carcinoma, Skin Appendage; Keratoacanthoma; Basal Cell Nevus Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi | Details |
| Bifikafusp alfa | L19-IL-2 | Phase 3 Clinical | Philogen Spa | Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis | Details |
| BNZ-1 | BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01; EQ101; EQ-101 | Phase 2 Clinical | Bioniz Therapeutics Inc | Alopecia; Alopecia Areata; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic | Details |
| umitrelimorgene autodencel | ITI-1000 | Phase 2 Clinical | Immunomic Therapeutics Inc | Glioblastoma | Details |
| S-95007 | S-95007 | Phase 2 Clinical | Laboratoires Servier | Immune System Diseases; Inflammation | Details |
| AU-007 | BD-8; AU-007; BDG-8 | Phase 2 Clinical | Biolojic Design Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| XTX-202 | XTX-202 | Phase 2 Clinical | Xilio Development Inc, Xilio Therapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Melanoma | Details |
| LAT-010 | LAT010; LAT-010 | Phase 2 Clinical | Latticon Antibody Therapeutics Inc | Solid tumours | Details |
| COYA-302 | COYA302; COYA 302; COYA-302 | Phase 2 Clinical | Coya Therapeutics Inc | Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis | Details |
| AVB-001 | AVB-001 | Phase 2 Clinical | Avenge Bio Inc | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| Saltikva | Phase 2 Clinical | Salspera LLC | Pancreatic Neoplasms | Details | |
| LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) | Phase 2 Clinical | Tcrcure Biopharma Ltd | Nasopharyngeal Carcinoma | Details | |
| Interleukin-2 gene therapy (St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital, National Cancer Institute | Neuroblastoma | Details | |
| T20K | T-20K | Phase 1 Clinical | Cyxone | Multiple Sclerosis | Details |
| SIM-0278 | ALM-223; SIM0278 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic; Dermatitis, Atopic | Details |
| Mableukin 2PD1 (Anwita Biosciences) | AWT020; AWT-020 | Phase 1 Clinical | Anwita Biosciences Inc | Neoplasms; Autoimmune Diseases of the Nervous System | Details |
| AB-248 | AB-248 | Phase 1 Clinical | Asher Biotherapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| ASP-1012 | VET2-L2; ASP-1012; ASP1012 | Phase 1 Clinical | KaliVir Immunotherapeutics Inc | Solid tumours | Details |
| STK-012 | STK-012 | Phase 1 Clinical | Synthekine Inc | Solid tumours; Mismatch Repair Deficient Cancer; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| IL2 CD25 fusion protein (Bristol-Myers Squibb) | Phase 1 Clinical | University Of Miami | Autoimmune Diseases | Details | |
| M5A-IL2 Immunocytokine | M5A-ICK | Phase 1 Clinical | National Cancer Institute, City Of Hope National Medical Center | Breast Neoplasms; Colorectal Neoplasms | Details |
| DF-6215 | DF6215; DF-6215 | Phase 1 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
| Dodekin | Phase 1 Clinical | Philogen Spa | Solid tumours; Neoplasm Metastasis | Details | |
| KB-707 | KB-707; KB707 | Phase 1 Clinical | Krystal Biotech Inc | Solid tumours; Skin Melanoma; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Neoplasms; Sarcoma; Osteosarcoma; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular | Details |
| attIL2-T cell therapy | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Soft Tissue Neoplasms; Osteosarcoma; Sarcoma | Details | |
| Autologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics) | HV-101; HV101 | Phase 1 Clinical | Hervor Therapeutics, Tcrcure Biopharma Ltd, Hangzhou Houwu Biomedical Technology Co Ltd | Solid tumours | Details |
| KY-0118 | KY-0118; KY0118 | Phase 1 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| VIS171 | VIS-171; VIS171 | Phase 1 Clinical | Visterra Inc | Autoimmune Diseases | Details |
| MK-1484 | MK-1484; SP-482 | Phase 1 Clinical | Merck & Co Inc, Sutro Biopharma Inc | Solid tumours | Details |
| SAR-444336 | SAR-444336 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| RS-2102 | RS2102 | Phase 1 Clinical | Reistone Biopharma Co Ltd | Dermatitis, Atopic | Details |
| RG-6279 | RG-6279 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Solid tumours | Details |
| BNT-153 | BNT-153 | Phase 1 Clinical | Biontech Se | Solid tumours | Details |
| Igrelimogene litadenorepvec | PM-1016; PM1016; TILT-123 | Phase 1 Clinical | Tilt Biotherapeutics Ltd | Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Small Cell Lung Carcinoma; Peritoneal Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Melanoma; Carcinoma, Hepatocellular | Details |
This web search service is supported by Google Inc.
A-Z
